- Home
- NEXN vs MNPR Comparison
NEXN vs MNPR Comparison
Compare NEXN & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEXN | MNPR |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | Israel | United States |
| Employees | 909 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.1M | 368.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NEXN | MNPR |
|---|---|---|
| Price | $8.59 | $59.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $11.56 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 227.7K | 149.2K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.60 | $29.18 |
| 52 Week High | $11.59 | $105.00 |
Technical Indicators
Market Signals| Indicator | NEXN | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 47.52 |
| Support Level | $8.01 | $56.02 |
| Resistance Level | $8.62 | $60.67 |
| Average True Range (ATR) | 0.35 | 3.50 |
| MACD | -0.01 | -0.56 |
| Stochastic Oscillator | 77.38 | 15.69 |
Price Performance
Historical ComparisonAbout NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and TV that helps empower advertisers, agencies, digital publishers, broadcasters, and others. The Digital Advertising Ecosystem of the company includes demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. The company operates in America, APAC, EMEA, and Rest of America, with majority revenue from America.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.